Amazon Web Services launched Amazon Bio Discovery, an agentic AI application with 40+ biology models to speed early-stage drug discovery for scientists.

Novo Nordisk will integrate OpenAI's AI across its operations to accelerate drug development, including obesity and diabetes treatments.

The National Academy of Medicine formally launched its 'Patient Safety in the Era of AI' initiative on March 4, 2026, bringing together health care, technology, and policy leaders to develop a national strategy for leveraging AI to prevent patient harm.

Merck partners with Mayo Clinic to leverage AI, advanced analytics, and the Mayo Clinic Platform's genomic and clinical data for drug discovery and precision medicine. The collaboration initially targets inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.

AlphaFold Protein Database reaches 3M+ users globally. New AI tools include AI co-scientist, EarthAI, and AlphaGenome for cancer research and scientific discovery.

Demis Hassabis reveals 17 AI drug development projects at Davos, predicting robotics breakthrough and golden age of scientific discovery.

BrainIAC foundation model predicts brain age, dementia risk, and cancer survival from MRI scans. Trained on 48,965 scans, published in Nature Neuroscience.

Epic Systems, controlling 42% of hospital EHR market, unveils AI Charting to actively generate clinical notes, orders, and diagnoses.

Google launches first-of-its-kind nationwide randomized study with Included Health to evaluate conversational AI in real-world virtual care workflows.

Utah has partnered with health tech startup Doctronic to launch an AI system that will autonomously renew approximately 200 common medications after performing clinical evaluations. The initiative raises critical questions about FDA oversight authority as Doctronic claims its AI doctor doesn't require regulatory approval.

The landmark MASAI trial reveals that AI-assisted mammography screening improves breast cancer detection by 28% and reduces radiologist workload by 44%, with fewer interval cancers.

Google DeepMind unveils AlphaGenome, a groundbreaking AI tool that analyzes up to 1 million letters of DNA code to predict how mutations affect gene regulation, potentially paving the way for new treatments for heart disease, cancer, and autoimmune disorders.

Stanford researchers have developed SleepFM, an AI model that analyzes data from one night of sleep to predict the future risk of more than 130 diseases, including cancer and dementia, with over 80% accuracy.

A new generative AI can analyze blood cells to detect subtle signs of diseases like leukemia with greater accuracy than human experts, while also being able to assess its own uncertainty.

MIT Technology Review's latest newsletter explores OpenAI's new ChatGPT Health product, which caters to 230 million weekly health-related queries, and the escalating conflict between federal and state-level efforts to regulate artificial intelligence in the United States.

In a major push for data security, SAP and Fresenius are collaborating on a 'sovereign' AI platform for the healthcare industry. The multi-million euro initiative aims to create a secure, compliant environment for processing sensitive medical data, enabling hospitals to scale AI applications safely.

The pharmaceutical industry is poised for a paradigm shift from Research & Development (R&D) to Research & Prediction (R&P), with agentic AI expected to deliver the first fully predictive drug development pipeline by 2026.